Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.830
+0.040 (1.43%)
At close: Mar 13, 2026, 4:00 PM EDT
2.830
0.00 (0.00%)
After-hours: Mar 13, 2026, 8:00 PM EDT

Protalix BioTherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
61.8453.465.4947.6438.3562.9
Revenue Growth (YoY)
35.41%-18.47%37.48%24.22%-39.03%15.00%
Cost of Revenue
26.2624.3222.9819.5916.3510.87
Gross Profit
35.5829.0842.5128.052252.03
Selling, General & Admin
11.1612.1914.9611.7112.7311.15
Research & Development
18.0612.9717.0929.3529.7338.17
Total Operating Expenses
29.2125.1632.0541.0642.4649.32
Operating Income
6.373.9210.46-13.01-20.462.71
Interest Income
1.091.31.291.150.40.44
Interest Expense
-0.98-1.06-3.18-2.53-7.52-9.67
Other Non-Operating Income (Expense)
0.120.24-1.89-1.38-7.12-9.23
Total Non-Operating Income (Expense)
0.230.47-3.79-2.77-14.24-18.47
Pretax Income
6.64.396.67-15.78-34.7-15.76
Provision for Income Taxes
0.331.220.250.53--
Net Income
5.812.938.31-14.93-27.58-6.52
Net Income to Common
5.812.938.31-14.93-27.58-6.52
Net Income Growth
--64.73%----
Shares Outstanding (Basic)
767368484429
Shares Outstanding (Diluted)
868182484429
Shares Change (YoY)
9.20%-1.66%70.04%9.81%51.43%96.44%
EPS (Basic)
0.070.040.12-0.31-0.62-0.22
EPS (Diluted)
0.070.040.09-0.31-0.62-0.22
EPS Growth
--55.56%----
Free Cash Flow
-11.697.39-2.47-25.63-11.74-26.76
Free Cash Flow Per Share
-0.140.09-0.03-0.53-0.27-0.92
Gross Margin
57.54%54.46%64.91%58.87%57.37%82.71%
Operating Margin
10.30%7.34%15.97%-27.32%-53.36%4.31%
Profit Margin
9.96%5.93%9.80%-34.24%-90.49%-25.05%
FCF Margin
-18.91%13.84%-3.77%-53.80%-30.62%-42.55%
EBITDA
7.785.2211.65-11.93-19.344.01
EBITDA Margin
12.58%9.78%17.79%-25.04%-50.44%6.38%
EBIT
6.373.9210.46-13.01-20.462.71
EBIT Margin
10.30%7.34%15.97%-27.32%-53.36%4.31%
Effective Tax Rate
6.68%27.83%3.81%-3.36%0.00%0.00%
Updated Nov 13, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q